Cerus Corp (CERS) 5.53 $CERS
Cerus to Release Fourth Quarter 2014 Results on February 26, 2015
Business Wire - Fri Feb 13, 7:30AM CST
Cerus Corporation (NASDAQ:CERS) announced today that its fourth quarter results will be released on Thursday, February 26, 2015, after the close of the stock market. The company will host a conference call and webcast at 4:15 PM ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook.
CERS: 5.53 (+0.08)
Cerus and SunCoast Blood Bank Enter Into Agreement for the Use of INTERCEPT Platelets and Plasma
Business Wire - Thu Feb 05, 7:31AM CST
Cerus Corporation (NASDAQ: CERS) and the SunCoast Blood Bank (SCBB) announced today that they have signed a three-year purchase agreement for the INTERCEPT Blood System for platelets and plasma. SCBB collects over 45,000 units of blood products, including 6,000 units of platelets and over 5,500 plasma units per year, to support 12 hospitals.
CERS: 5.53 (+0.08)
Cerus and Blood Bank of Delmarva Enter into Agreement for the Use of INTERCEPT Platelets and Plasma
Business Wire - Wed Feb 04, 7:31AM CST
Cerus Corporation (NASDAQ: CERS) and the Blood Bank of Delmarva (BBD) announced today that they have signed a three-year purchase agreement for the INTERCEPT Blood System for platelets and plasma. BBD provides blood transfusion products and services to hospitals and patients in Delaware, Cecil County, Maryland, as well as Maryland's and Virginia's Eastern Shores. BBD supplies approximately 13,000 platelet and 21,000 plasma units per year.
CERS: 5.53 (+0.08)
Ash Stevens to Manufacture Amotosalen Active Pharmaceutical Ingredient for Cerus' INTERCEPT Blood System
PR Newswire - Wed Jan 28, 7:00AM CST
Ash Stevens, Inc. (ASI), a leading provider of global contract pharmaceutical drug substance development and API (Active Pharmaceutical Ingredient) manufacturing services, is pleased to announce the U.S Food and Drug Administration (FDA) has approved ASI's manufacturing facility in Riverview, Michigan for the manufacture of Amotosalen, the API in Cerus Corporation's (NASDAQ: CERS) INTERCEPT Blood System. The INTERCEPT Blood System recently received FDA approval for ex vivo preparation of pathogen-reduced plasma and platelet components in order to reduce the risk of transfusion-transmitted infection (TTI).
CERS: 5.53 (+0.08)
Health Care Supplies Stocks Technical Review - Cerus, Unilife, DENTSPLY Intl., Alere, and Align Technology
PR Newswire - Thu Jan 22, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Cerus Corporation (NASDAQ: CERS), Unilife Corporation (NASDAQ: UNIS), DENTSPLY International Inc. (NASDAQ: XRAY), Alere Inc. (NYSE: ALR), and Align Technology Inc. (NASDAQ: ALGN). Free research report on Cerus can be accessed at http://get.Investor-Edge.com/pdf/?c=Cerus&...amp;s=CERS. On Wednesday, January 21, 2015, the NASDAQ Composite ended at 4,667.42, up 0.27%, the Dow Jones Industrial Average advanced 0.22%, to finish the day at 17,554.28, and the S&P 500 closed at 2,032.12, up 0.47%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 814.90, up 0.11%, with the index also advancing 10.82% in the previous three months. Register for your complimentary reports at the links given below.
CERS: 5.53 (+0.08), ALGN: 56.90 (-0.34), UNIS: 4.32 (+0.06), ALR: 43.40 (-0.40), XRAY: 52.74 (+0.32)
Uptrend Call Working As Cerus Stock Rises 39.4% (CERS)
Comtex SmarTrend(R) - Fri Jan 16, 5:18PM CST
SmarTrend identified an Uptrend for Cerus (NASDAQ:CERS) on October 16th, 2014 at $4.23. In approximately 3 months, Cerus has returned 39.41% as of today's recent price of $5.89.
CERS: 5.53 (+0.08)
Cerus Up 43.8% Since SmarTrend Uptrend Call (CERS)
Comtex SmarTrend(R) - Fri Jan 09, 11:19AM CST
SmarTrend identified an Uptrend for Cerus (NASDAQ:CERS) on October 16th, 2014 at $4.23. In approximately 3 months, Cerus has returned 43.79% as of today's recent price of $6.08.
CERS: 5.53 (+0.08)
Cerus prices offering
Seeking Alpha - at Seeking Alpha - Wed Jan 07, 8:00AM CST
CERS: 5.53 (+0.08)
Cerus Prices $70.0 Million Public Offering of Common Stock
Business Wire - Wed Jan 07, 7:01AM CST
Cerus Corporation (NASDAQ:CERS) today announced the pricing of an underwritten public offering of 12,727,273 shares of its common stock, offered at a price to the public of $5.50 per share for expected gross proceeds of $70.0 million. The net proceeds to Cerus from this offering are expected to be approximately $65.5 million, after deducting the underwriting discount and estimated offering expenses payable by Cerus. The offering is expected to close on or about January 12, 2015, subject to customary closing conditions. In addition, Cerus has granted the underwriters a 30-day option to purchase up to an additional 1,909,090 shares of its common stock to cover overallotments, if any. Cerus anticipates using the net proceeds from the offering for continued development activities related to the INTERCEPT Blood System, to fund commercialization efforts for the INTERCEPT Blood System in the United States and elsewhere, and for other general corporate purposes, including regulatory activity, selling, general and administrative expenses and working capital.
CERS: 5.53 (+0.08)
Nasdaq stocks posting largest percentage decreases
AP - Tue Jan 06, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
CERS: 5.53 (+0.08), QADB: 17.59 (+0.05), CTSO: 8.20 (+0.18), QADA: 20.36 (+0.14), CLDN: 16.45 (-0.05), GWGH: 6.64 (unch), HEES: 22.94 (+0.77), PEIX: 9.82 (+0.15), MTEX: 23.89 (+0.69), AREX: 8.15 (+0.27)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 4:35PM CST
CERS: 5.53 (+0.08), RICE: 19.13 (-0.22), ECR: 7.29 (+0.12), ANTH: 3.84 (+0.06), NERV: 4.68 (+0.09), AU: 12.33 (+0.36), JNUG: 30.90 (+1.14), WTI: 6.55 (+0.41), CYBX: 57.03 (+0.26), GST: 2.89 (unch)
Cerus Announces Proposed Public Offering of Common Stock
Business Wire - Mon Jan 05, 3:01PM CST
Cerus Corporation (NASDAQ: CERS) today announced that it intends to offer and sell shares of its common stock, subject to market and other conditions, in an underwritten public offering. Cerus also expects to grant the underwriters a 30-day option to purchase additional shares of common stock to cover overallotments, if any. Cerus anticipates using the net proceeds from the offering for continued development activities related to the INTERCEPT Blood System, to fund commercialization efforts for the INTERCEPT Blood System in the United States and elsewhere, and for other general corporate purposes, including regulatory activity, selling, general and administrative expenses and working capital.
CERS: 5.53 (+0.08)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 8:10AM CST
CERS: 5.53 (+0.08), E: 36.31 (+0.69), SSL: 41.10 (+0.96), CNAT: 5.92 (+0.10), SDRL: 12.32 (-0.70), NBG: 1.61 (+0.18), BCLI: 3.86 (-0.02), URZ: 1.18 (+0.01), PBR: 6.98 (+0.44), ISIS: 63.86 (-0.43), KITE: 62.59 (+0.82), PLX: 1.84 (-0.04), CEMP: 27.68 (+1.25), STXS: 2.27 (+0.13)
Intercept-treated red blood cells on par with conventional RBCs in study
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 7:26AM CST
CERS: 5.53 (+0.08)
Cerus Reports EU Phase 3 Clinical Trial of INTERCEPT Red Blood Cells Met Primary Endpoint
Business Wire - Mon Jan 05, 6:45AM CST
Cerus Corporation (NASDAQ:CERS) announced today that its European Phase 3 clinical trial of red blood cells treated with the INTERCEPT Blood System for acute anemia in cardiovascular surgery patients met the primary endpoint. Preliminary analysis demonstrated that the mean hemoglobin content (53.1g) of INTERCEPT-treated red blood cell components (RBCs) on day 35 of storage met the protocol-defined criteria for equivalence based on the inferiority margin of 5g compared to conventional red blood cell components (55.8g). The investigators plan to submit data from the study for presentation at upcoming scientific congresses.
CERS: 5.53 (+0.08)
Cerus Shares Up 49.8% Since SmarTrend's Buy Recommendation (CERS)
Comtex SmarTrend(R) - Fri Jan 02, 9:55AM CST
SmarTrend identified an Uptrend for Cerus (NASDAQ:CERS) on October 16th, 2014 at $4.23. In approximately 3 months, Cerus has returned 49.82% as of today's recent price of $6.33.
CERS: 5.53 (+0.08)
Cerus Corporation Reports Phase II Red Blood Cells Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 29, 3:00PM CST
Cerus Corporation (CERS) announced that its phase II study on red blood cells when treated with the INTERCEPT blood system has met the primary endpoint.
CERS: 5.53 (+0.08), LCI: 57.78 (-0.91), CBST: 101.94 (+0.14), BIOD: 1.38 (-0.14)
Shares of CERS Up 57.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Dec 26, 9:14AM CST
SmarTrend identified an Uptrend for Cerus (NASDAQ:CERS) on October 16th, 2014 at $4.23. In approximately 2 months, Cerus has returned 57.87% as of today's recent price of $6.67.
CERS: 5.53 (+0.08)
Interesting CERS Put And Call Options For August 2015
at The Street - Wed Dec 24, 11:43AM CST
Investors in Cerus Corp. saw new options become available this week, for the August 2015 expiration.
CERS: 5.53 (+0.08)
Today's Dead Cat Bounce Stock Is Cerus (CERS)
at The Street - Wed Dec 24, 9:02AM CST
Trade-Ideas LLC identified Cerus (CERS) as a "dead cat bounce" (down big yesterday but up big today) candidate
CERS: 5.53 (+0.08)
Cerus to Release Fourth Quarter 2014 Results on February 26, 2015
Business Wire - Fri Feb 13, 7:30AM CST
Cerus Corporation (NASDAQ:CERS) announced today that its fourth quarter results will be released on Thursday, February 26, 2015, after the close of the stock market. The company will host a conference call and webcast at 4:15 PM ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook.
CERS: 5.53 (+0.08)
Cerus and SunCoast Blood Bank Enter Into Agreement for the Use of INTERCEPT Platelets and Plasma
Business Wire - Thu Feb 05, 7:31AM CST
Cerus Corporation (NASDAQ: CERS) and the SunCoast Blood Bank (SCBB) announced today that they have signed a three-year purchase agreement for the INTERCEPT Blood System for platelets and plasma. SCBB collects over 45,000 units of blood products, including 6,000 units of platelets and over 5,500 plasma units per year, to support 12 hospitals.
CERS: 5.53 (+0.08)
Cerus and Blood Bank of Delmarva Enter into Agreement for the Use of INTERCEPT Platelets and Plasma
Business Wire - Wed Feb 04, 7:31AM CST
Cerus Corporation (NASDAQ: CERS) and the Blood Bank of Delmarva (BBD) announced today that they have signed a three-year purchase agreement for the INTERCEPT Blood System for platelets and plasma. BBD provides blood transfusion products and services to hospitals and patients in Delaware, Cecil County, Maryland, as well as Maryland's and Virginia's Eastern Shores. BBD supplies approximately 13,000 platelet and 21,000 plasma units per year.
CERS: 5.53 (+0.08)
Ash Stevens to Manufacture Amotosalen Active Pharmaceutical Ingredient for Cerus' INTERCEPT Blood System
PR Newswire - Wed Jan 28, 7:00AM CST
Ash Stevens, Inc. (ASI), a leading provider of global contract pharmaceutical drug substance development and API (Active Pharmaceutical Ingredient) manufacturing services, is pleased to announce the U.S Food and Drug Administration (FDA) has approved ASI's manufacturing facility in Riverview, Michigan for the manufacture of Amotosalen, the API in Cerus Corporation's (NASDAQ: CERS) INTERCEPT Blood System. The INTERCEPT Blood System recently received FDA approval for ex vivo preparation of pathogen-reduced plasma and platelet components in order to reduce the risk of transfusion-transmitted infection (TTI).
CERS: 5.53 (+0.08)
Health Care Supplies Stocks Technical Review - Cerus, Unilife, DENTSPLY Intl., Alere, and Align Technology
PR Newswire - Thu Jan 22, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Cerus Corporation (NASDAQ: CERS), Unilife Corporation (NASDAQ: UNIS), DENTSPLY International Inc. (NASDAQ: XRAY), Alere Inc. (NYSE: ALR), and Align Technology Inc. (NASDAQ: ALGN). Free research report on Cerus can be accessed at http://get.Investor-Edge.com/pdf/?c=Cerus&...amp;s=CERS. On Wednesday, January 21, 2015, the NASDAQ Composite ended at 4,667.42, up 0.27%, the Dow Jones Industrial Average advanced 0.22%, to finish the day at 17,554.28, and the S&P 500 closed at 2,032.12, up 0.47%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 814.90, up 0.11%, with the index also advancing 10.82% in the previous three months. Register for your complimentary reports at the links given below.
CERS: 5.53 (+0.08), ALGN: 56.90 (-0.34), UNIS: 4.32 (+0.06), ALR: 43.40 (-0.40), XRAY: 52.74 (+0.32)
Uptrend Call Working As Cerus Stock Rises 39.4% (CERS)
Comtex SmarTrend(R) - Fri Jan 16, 5:18PM CST
SmarTrend identified an Uptrend for Cerus (NASDAQ:CERS) on October 16th, 2014 at $4.23. In approximately 3 months, Cerus has returned 39.41% as of today's recent price of $5.89.
CERS: 5.53 (+0.08)
Cerus Up 43.8% Since SmarTrend Uptrend Call (CERS)
Comtex SmarTrend(R) - Fri Jan 09, 11:19AM CST
SmarTrend identified an Uptrend for Cerus (NASDAQ:CERS) on October 16th, 2014 at $4.23. In approximately 3 months, Cerus has returned 43.79% as of today's recent price of $6.08.
CERS: 5.53 (+0.08)
Cerus prices offering
Seeking Alpha - at Seeking Alpha - Wed Jan 07, 8:00AM CST
CERS: 5.53 (+0.08)
Cerus Prices $70.0 Million Public Offering of Common Stock
Business Wire - Wed Jan 07, 7:01AM CST
Cerus Corporation (NASDAQ:CERS) today announced the pricing of an underwritten public offering of 12,727,273 shares of its common stock, offered at a price to the public of $5.50 per share for expected gross proceeds of $70.0 million. The net proceeds to Cerus from this offering are expected to be approximately $65.5 million, after deducting the underwriting discount and estimated offering expenses payable by Cerus. The offering is expected to close on or about January 12, 2015, subject to customary closing conditions. In addition, Cerus has granted the underwriters a 30-day option to purchase up to an additional 1,909,090 shares of its common stock to cover overallotments, if any. Cerus anticipates using the net proceeds from the offering for continued development activities related to the INTERCEPT Blood System, to fund commercialization efforts for the INTERCEPT Blood System in the United States and elsewhere, and for other general corporate purposes, including regulatory activity, selling, general and administrative expenses and working capital.
CERS: 5.53 (+0.08)
Nasdaq stocks posting largest percentage decreases
AP - Tue Jan 06, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
CERS: 5.53 (+0.08), QADB: 17.59 (+0.05), CTSO: 8.20 (+0.18), QADA: 20.36 (+0.14), CLDN: 16.45 (-0.05), GWGH: 6.64 (unch), HEES: 22.94 (+0.77), PEIX: 9.82 (+0.15), MTEX: 23.89 (+0.69), AREX: 8.15 (+0.27)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 4:35PM CST
CERS: 5.53 (+0.08), RICE: 19.13 (-0.22), ECR: 7.29 (+0.12), ANTH: 3.84 (+0.06), NERV: 4.68 (+0.09), AU: 12.33 (+0.36), JNUG: 30.90 (+1.14), WTI: 6.55 (+0.41), CYBX: 57.03 (+0.26), GST: 2.89 (unch)
Cerus Announces Proposed Public Offering of Common Stock
Business Wire - Mon Jan 05, 3:01PM CST
Cerus Corporation (NASDAQ: CERS) today announced that it intends to offer and sell shares of its common stock, subject to market and other conditions, in an underwritten public offering. Cerus also expects to grant the underwriters a 30-day option to purchase additional shares of common stock to cover overallotments, if any. Cerus anticipates using the net proceeds from the offering for continued development activities related to the INTERCEPT Blood System, to fund commercialization efforts for the INTERCEPT Blood System in the United States and elsewhere, and for other general corporate purposes, including regulatory activity, selling, general and administrative expenses and working capital.
CERS: 5.53 (+0.08)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 8:10AM CST
CERS: 5.53 (+0.08), E: 36.31 (+0.69), SSL: 41.10 (+0.96), CNAT: 5.92 (+0.10), SDRL: 12.32 (-0.70), NBG: 1.61 (+0.18), BCLI: 3.86 (-0.02), URZ: 1.18 (+0.01), PBR: 6.98 (+0.44), ISIS: 63.86 (-0.43), KITE: 62.59 (+0.82), PLX: 1.84 (-0.04), CEMP: 27.68 (+1.25), STXS: 2.27 (+0.13)
Intercept-treated red blood cells on par with conventional RBCs in study
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 7:26AM CST
CERS: 5.53 (+0.08)
Cerus Reports EU Phase 3 Clinical Trial of INTERCEPT Red Blood Cells Met Primary Endpoint
Business Wire - Mon Jan 05, 6:45AM CST
Cerus Corporation (NASDAQ:CERS) announced today that its European Phase 3 clinical trial of red blood cells treated with the INTERCEPT Blood System for acute anemia in cardiovascular surgery patients met the primary endpoint. Preliminary analysis demonstrated that the mean hemoglobin content (53.1g) of INTERCEPT-treated red blood cell components (RBCs) on day 35 of storage met the protocol-defined criteria for equivalence based on the inferiority margin of 5g compared to conventional red blood cell components (55.8g). The investigators plan to submit data from the study for presentation at upcoming scientific congresses.
CERS: 5.53 (+0.08)
Cerus Shares Up 49.8% Since SmarTrend's Buy Recommendation (CERS)
Comtex SmarTrend(R) - Fri Jan 02, 9:55AM CST
SmarTrend identified an Uptrend for Cerus (NASDAQ:CERS) on October 16th, 2014 at $4.23. In approximately 3 months, Cerus has returned 49.82% as of today's recent price of $6.33.
CERS: 5.53 (+0.08)
Cerus Corporation Reports Phase II Red Blood Cells Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 29, 3:00PM CST
Cerus Corporation (CERS) announced that its phase II study on red blood cells when treated with the INTERCEPT blood system has met the primary endpoint.
CERS: 5.53 (+0.08), LCI: 57.78 (-0.91), CBST: 101.94 (+0.14), BIOD: 1.38 (-0.14)
Shares of CERS Up 57.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Dec 26, 9:14AM CST
SmarTrend identified an Uptrend for Cerus (NASDAQ:CERS) on October 16th, 2014 at $4.23. In approximately 2 months, Cerus has returned 57.87% as of today's recent price of $6.67.
CERS: 5.53 (+0.08)
Interesting CERS Put And Call Options For August 2015
at The Street - Wed Dec 24, 11:43AM CST
Investors in Cerus Corp. saw new options become available this week, for the August 2015 expiration.
CERS: 5.53 (+0.08)
Today's Dead Cat Bounce Stock Is Cerus (CERS)
at The Street - Wed Dec 24, 9:02AM CST
Trade-Ideas LLC identified Cerus (CERS) as a "dead cat bounce" (down big yesterday but up big today) candidate
CERS: 5.53 (+0.08)
